Dermatol. praxi. 2009;3(4):173-177

Systemic autoimmune diseases (I.)

MUDr.Martin ®urek
III. interní klinika FN Olomouc

Systemic autoimmune diseases are affecting many organ systems. The skin and its adnexa are often involved. In our paper we present

concise review of clinical manifestation, diagnosis and basic treatment of those diseases.

myopathies, Sjogren syndrome.

Keywords: systemic autoimmune diseases, systemic lupus erythematosus, progressive systemic sclerosis, idiopathic inflammatory

Published: May 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
®urek M. Systemic autoimmune diseases (I.). Dermatol. praxi. 2009;3(4):173-177.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Vecovský J. Autoimunitní systémová onemocnění. Triton 1998: 13-27.
    2. Systemic lupus erytematosus. In: Imboden, et al. Current Rheumatology diagnosis and treatment. Second edition. Lange Medical Books/Mc Graw-Hill 2007: 203-217.
    3. Bertsias G, Ioannidis JP, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008; 67(2): 195-205. Go to original source... Go to PubMed...
    4. Scleroderma. In: Imboden, et al. Current Rheumatology diagnosis and treatment. Second edition. Lange Medical Books/Mc Graw-Hill 2007: 228-236.
    5. Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am. 2003; 29(2): 239-254. Go to original source... Go to PubMed...
    6. American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980; 23(5): 581-590. Go to original source... Go to PubMed...
    7. Ingegnoli F, Boracchi P, Gualtierotti R, et. al. Prognostic model based on nailfold capillaroscopy for identifying Raynaud's phenomenon patients at high risk for the development of a scleroderma spectrum disorder: PRINCE (prognostic index for nailfold capillaroscopic examination). Arthritis Rheum. 2008; 58(7): 2174-2182. Go to original source... Go to PubMed...
    8. Primary Sjogren syndrome. In: Imboden, et al. Current Rheumatology diagnosis and treatment. Second edition. Lange Medical Books/Mc Graw-Hill 2007: 237-245.
    9. Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjögren syndrome. Arch Intern Med. 2004; 164(12): 1275-1284. Go to original source... Go to PubMed...
    10. Ramos-Casals M, Anaya JM, García-Carrasco M, et al. Cutaneous vasculitis in primary Sjögren syndrome: classification and clinical significance of 52 patients. Medicine (Baltimore). 2004; 83(2): 96-106. Go to original source... Go to PubMed...
    11. Polymyositis and dermatomyositis. In: Imboden, et al. Current Rheumatology diagnosis and treatment. Second edition. Lange Medical Books/Mc Graw-Hill 2007: 246-255.
    12. Callen JP. Dermatomyositis. Lancet. 2000; 355(9197): 53-57. Review. Go to original source... Go to PubMed...

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.